The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medtronic's revenues will grow 2.9% and EPS will expand 8.3%.
The average estimate for revenue is $4.03 billion. On the bottom line, the average EPS estimate is $0.91.
Last quarter, Medtronic tallied revenue of $4.10 billion. GAAP reported sales were 1.8% higher than the prior-year quarter's $4.02 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.88. GAAP EPS of $0.63 for Q2 were 23% lower than the prior-year quarter's $0.82 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.1%, 100 basis points worse than the prior-year quarter. Operating margin was 28.3%, 20 basis points worse than the prior-year quarter. Net margin was 15.8%, 590 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $16.53 billion. The average EPS estimate is $3.67.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,706 members out of 1,797 rating the stock outperform, and 91 members rating it underperform. Among 531 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 519 give Medtronic a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medtronic is outperform, with an average price target of $45.20.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Medtronic. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Medtronic to My Watchlist.